Nascent Biotech (NBIO) 10-K 15 Jun 22 2022 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Mar. 31, 2022	Jun. 15, 2022	Sep. 30, 2021
Cover [Abstract]
Entity Registrant Name	NASCENT BIOTECH INC.
Entity Central Index Key	0001622057
Document Type	10-K
Amendment Flag	false
Entity Voluntary Filers	No
Current Fiscal Year End Date	--03-31
Entity Well Known Seasoned Issuer	No
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Mar. 31, 2022
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Entity Common Stock Shares Outstanding		115,013,175
Entity Public Float			$ 6,922,180
Document Annual Report	true
Document Transition Report	false
Entity File Number	000-55299
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	46-5001940
Entity Interactive Data Current	Yes
Entity Address Address Line 1	623 17th Street Suite 4
Entity Address City Or Town	Vero Beach
Entity Address Postal Zip Code	32960
City Area Code	612
Local Phone Number	961-5656
Entity Address State Or Province	FL
Auditor Name	Spokane
Auditor Location	Washington
Auditor Firm Id	5525

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2022	Mar. 31, 2021
Current assets:
Cash	$ 94,414	$ 1,435
Accounts receivable	0	750,000
Prepaid	11,000	0
Total current assets	105,414	751,435
Total assets	105,414	751,435
Current liabilities:
Accounts payable and accrued expense	776,890	636,831
Convertible note- net of discount	0	161,736
Derivative liability	0	302,156
Due related parties	0	123,217
Total current liabilities	776,890	1,223,940
Total liabilities	776,890	1,223,940
Commitments and Contingencies	0	0
Stockholders' equity:
Common stock, $0.001 par value, 500,000,000 authorized, 111,313,175 and 104,834,083 issued and outstanding, respectively	111,313	104,834
Additional paid-in capital	18,039,017	17,774,023
Accumulated deficit	(18,821,806)	(18,351,416)
Total stockholders' equity (deficit)	(671,476)	(472,505)
Total liabilities and stockholders' equity	105,414	751,435
Series A Preferred Stock [Member]
Stockholders' equity:
Preferred stock Value	$ 0	$ 54

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2022	Mar. 31, 2021
Stockholders' deficit
Common stock, shares par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	111,313,175	104,834,083
Common stock, shares outstanding	111,313,175	104,834,083
Preferred stock, shares par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	50,000,000	50,000,000
Series A Preferred Stock [Member]
Stockholders' deficit
Preferred stock, shares issued	0	54,130
Preferred stock, shares outstanding	0	54,130

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
CONSOLIDATED STATEMENTS OF OPERATIONS
Revenue	$ 1,000,000	$ 750,000
Operating expenses:
Consulting expense	547,933	1,469,171
General and administrative expense	379,424	359,259
Clinical trials	332,289	0
Research and development	197,406	321,938
Total operating expense	(1,457,052)	(2,150,368)
Income (loss) from operations	(457,052)	(1,400,368)
Other income (expense):
Interest income	12	5
Interest expense	(48,044)	(269,382)
Finance costs	(151,150)	(19,411)
Gain on debt forgiveness	5,000	151,308
Other expense	0	(369)
Original interest debt discount	(287,979)	(67,250)
Gain on change in fair value of derivative liabilities	468,823	646,705
Total other income (expense)	(13,338)	441,601
Net income (loss) before income tax	(470,390)	(958,767)
Income tax	0	0
Net income loss	$ (470,390)	$ (958,767)
Net income (loss) per share, basic and diluted	$ 0	$ (0.01)
Weighted average number of shares outstanding, basic and diluted	107,741,761	72,342,193

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (DEFICIT) - USD ($)	Total	Preferred Stock	Common Stock	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)
Balance at Mar. 31, 2020		60,000	44,890,262
Balance, amount at Mar. 31, 2020	$ (2,875,704)	$ 60	$ 44,890	$ 13,916,995	$ (16,837,649)
Common stock issued for service, shares			2,422,902
Common stock issued for service, amount	210,440	$ 0	$ 2,423	208,017	0
Common stock issued to related parties for service, shares			9,372,909
Common stock issued to related parties for service, amount	575,412		$ 9,373	566,039	0
Common stock issued for the conversion of preferred shares, shares		(745,870)	26,657,443
Common stock issued for the conversion of preferred shares, amount	14,275	$ (746)	$ 26,657	(11,636)	0
Common stock issued for accrued payables- related parties, shares			16,931,101
Common stock issued for accrued payables- related parties, amount	1,577,471	0	$ 16,931	1,560,540	0
Common stock issued for accounts payable, shares			577,287
Common stock issued for accounts payable, amount	44,801	0	$ 578	44,223	0
Common stock issued for convertible debt, shares			3,982,179
Common stock issued for convertible debt, amount	199,567	$ 0	$ 3,982	195,585	0
Preferred shares issued for cash, shares		640,000
Preferred shares issued for cash, amount	640,000	$ 640	0	639,360	0
Preferred shares issued for notes payable, shares		100,000
Preferred shares issued for notes payable, amount	100,000	$ 100	0	99,900	0
Deemed dividend from down round	0	0	0	555,000	(555,000)
Net loss	(958,767)	$ 0	$ 0	0	(958,767)
Balance, shares at Mar. 31, 2021		54,130	104,834,083
Balance, amount at Mar. 31, 2021	(472,505)		$ 104,834	17,774,023	(18,351,416)
Common stock issued for service, amount	110,835
Common stock issued for the conversion of preferred shares, shares		(54,130)	1,968,363
Common stock issued for the conversion of preferred shares, amount	0	$ (54)	$ 1,968	(1,914)	0
Net loss	(470,390)	0	$ 0	0	(470,390)
Common stock for service, shares			50,000
Common stock for service, amount	5,250	0	$ 50	5,200	0
Common stock to related parties for service, shares			1,513,719
Common stock to related parties for service, amount	110,836	0	$ 1,514	109,322	0
Common stock to related parties for conversion of payables, shares			2,407,010
Common stock to related parties for conversion of payables, amount	128,333	0	$ 2,407	125,926	0
Common stock for conversion of payables, shares			540,000
Common stock for conversion of payables, amount	27,000	$ 0	$ 540	26,460	0
Balance, shares at Mar. 31, 2022			111,313,175
Balance, amount at Mar. 31, 2022	$ (671,476)		$ 111,313	$ 18,039,017	$ (18,821,806)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (470,390)	$ (958,767)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation	5,250	210,440
Stock based compensation- related parties	110,835	575,412
Change in fair value of derivative liabilities	(468,823)	(646,705)
Debt discount	325,431	67,250
Financing cost	0	19,412
Gain on debt forgiveness	0	(151,308)
Changes in operating assets and liabilities:
Accounts receivable	750,000	(750,000)
Prepaid	(11,000)	0
Accounts payable and accrued expenses	167,060	230,400
Due to related parties	5,116	417,081
Net provided by (cash used) in operating activities	413,479	(986,783)
Cash flows from financing activities:
Proceeds from convertible note	200,000	295,000
Proceeds from notes payable	0	50,000
Proceeds from the sale of preferred shares and warrants	0	640,000
Repayment of convertible notes	(520,500)	0
Net cash provided by ( used in) financing activities	(320,500)	985,000
Net increase (decrease) in cash	92,979	(1,783)
Cash - beginning of year	1,435	3,218
Cash - end of year	94,414	1,435
SUPPLEMENT DISCLOSURES:
Interest paid	30,027	0
Income taxes paid	0	0
NON MONETARY TRANSACTIONS
Common stock issued for payables - related parties	$ 128,333	$ 1,577,471
Common stock issued for retiring preferred shares	1,968	142,757
Preferred shares issued for notes payable	$ 0	$ 100,000
Common stock issued for convertible debt	0	199,567
Common stock issued for accounts payable	$ 27,000	$ 44,081

ORGANIZATION AND NATURE OF OPER

ORGANIZATION AND NATURE OF OPERATIONS	12 Months Ended
	Mar. 31, 2022
ORGANIZATION AND NATURE OF OPERATIONS
NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS	NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS Nascent Biotech, Inc (“Nascent “the Company”) was incorporated on March 3, 2014 under the laws of the State of Nevada. On July 15, 2014 Biotech entered into a reverse merger with Jin-En Group International Holding Company (Jin-En). Jin-En issued 7,500,200 shares of its common stock for all the outstanding shares of Nascent Biotech, Inc. In addition, Jin-En cancelled 15,000,000 shares of its common stock. Prior to the merger Jin-En had 22,829,400 shares outstanding. Jin-En changed its name to Nascent Biotech, Inc. Jin-En had $19,000 of net liabilities at the date of the merger. The Company is actively developing its primary asset Pritumumab for the treatment of brain cancer and pancreatic cancer. Nascent is also actively researching other cancers that have a high probability of benefiting from the therapeutic effects of Pritumumab because they share a common target. Nascent is a clinical stage biopharmaceutical company that focuses on biologic drug candidates that are preparing for initial clinical testing for the treatment of brain and pancreatic cancer. The Company opened Phase 1 clinical studies during March 2021 and to date has enrolled patients in three cohorts of the four cohort study. Upon completion of the phase one trial, the Company will submit the data to the USFDA for approval to commence phase 2 clinical trials.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Mar. 31, 2022
SIGNIFICANT ACCOUNTING POLICIES
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles. The Company has elected a fiscal year ending on March 31. Principles of Consolidation The accompanying consolidated financial statements include the accounts of Nascent Biotech, Inc. and its wholly-owned subsidiary Nascent Biologics, Inc, which has been inactive since March 2015. All intercompany accounts and transactions have been eliminated. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The Company as of March 31, 2022 did not have any cash equivalents. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the periods. The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition, and results of operations is highly uncertain and subject to change. We considered the potential impact of the COVID-19 pandemic on our estimates and assumptions and there was not a material impact to our consolidated financial statements as of and for the year ended March 31, 2022. Actual results could differ from estimates making it reasonably possible that a change in the estimates could occur in the near term. Revenue recognition In April 2016, the FASB issued ASU 2016–10 Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. The amendments in this Update do not change the core principle of the guidance in Topic 606. Rather, the amendments in this Update clarify the following two aspects of Topic 606: identifying performance obligations and the licensing implementation guidance, while retaining the related principles for those areas. Topic 606 includes implementation guidance on (a) contracts with customers to transfer goods and services in exchange for consideration and (b) determining whether an entity’s promise to grant a license provides a customer with either a right to use the entity’s intellectual property (which is satisfied at a point in time) or a right to access the entity’s intellectual property (which is satisfied over time). The amendments are intended to render more detailed implementation guidance with the expectation to reduce the degree of judgement necessary to comply with Topic 606. ASC Topic 606 prescribes a new five-step model entities should follow in order to recognize revenue in accordance with the core principle. These five steps are: 1. Identify the contract(s) with a customer. 2. Identify the performance obligations in the contract. 3. Determine the transaction price. 4. Allocate the transaction price to the performance obligations in the contract. 5. Recognize revenue when (or as) the entity satisfied the performance obligations. The Company implemented the transition using the modified retrospective method of transition. The funds are not earned on milestones that have not been reached per the contract. Based on the cut off treatment of the recognition of revenue per the milestones specific to the license agreements, the Company has determined that there are no adjustments in the value of the revenue recognized from these contracts. The Company has one revenue stream, which is the milestone payments of the license agreement with BioRay Pharmaceutical which is not earned or billed until the milestone per the agreement is met. Accounts receivable Accounts receivable are carried at face value less any provisions for uncollectible amounts. Accounts receivable are receivables from a license agreement. No allowance for bad debt was considered necessary for the years ended March 31, 2022 and 2021, respectively. Stock-Based Compensation The Company accounts for stock-based compensation in accordance with the fair value recognition provision of the Financial Accounting Standards Board(“FASB”) Accounting Standards Codification (“ASC”) No 718. The Company issues restricted stock to employees and consultants for their services. Cost of these transactions are measured at fair value of the equity instrument issued at the date of grant. These shares are considered fully vested and the fair market value is recognized as the expense in the period granted. The Company recognized consulting expense and a corresponding increase to the additional paid in capital related to the stock issued for services. For agreements requiring future services the consulting expense is to be recognized ratably over the requisite service period. Research and Development Expense Research and development costs are expensed in the period they are incurred in accordance with ASC 730, Research and Development unless they meet specific criteria related to technical, market and financial feasibility, as determined by management, including but not limited to the establishment of a clearly defined future alternative use for the product, and the availability of adequate resources to complete the project. If all criteria are met, the costs are deferred and amortized over the expected useful life of the project or expensed as research and development as the material are consumed or written off if a product is abandoned. At March 31, 2022 and 2021, the Company had zero capitalized associated with materials held with a future alternative use. The cost of these materials was expensed as research and development as the materials are consumed or designated for usage. As the Company is preparing to begin clinical studies using a dose escalation method, it is not feasible to determine if the additional product will be needed for the brain cancer studies. Property and Equipment Property and equipment is recorded at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the expected useful life of the asset (3 to 5 years), beginning when the asset is available and ready for use. Expenditures associated with upgrades and enhancements that improve, add functionality, or otherwise extend the life of property and equipment are capitalized, while expenditures that do not, such as repairs and maintenance, are expensed as incurred. For the years ended March 31, 2022 and 2021, depreciation expense totaled zero, respectively. Impairment of Long-Lived Assets The Company reviews the carrying value of its long-lived assets annually or whenever events or changes in circumstances indicate that the historical-cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the asset by comparing the undiscounted future net cash flows expected to result from the asset to its carrying value. If the carrying value exceeds the undiscounted future net cash flows of the asset, an impairment loss is measured and recognized. An impairment loss is measured as the difference between the net book value and the fair value of the long-lived asset. Fair value is estimated based upon either discounted cash flow analysis or estimated salvage value. There was no impairment recognized during the years ended March 31, 2022 and 2021. Income Taxes Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company accounts for income taxes under the provisions of FASB ASC 740, Accounting for Income Taxes Basic and Diluted Net Income (Loss) per Share Basic net income (loss) per share calculations are calculated on the basis of the weighted average number of common shares outstanding during the year. During the year ended March 31, 2022 the Company had a net loss so the options and warrants outstanding were not part the loss per share calculation as they would be antidilutive. Diluted income (loss) per share calculations includes the dilutive effect of warrants and options on the weighted average of the per share calculation. Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, accounts payable and accrued expenses and shareholder loans. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. As defined in (Financial Accounting Standards Board ASC 820), fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilized the market data of similar entities in its industry or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. FASB ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). The three levels of the fair value hierarchy are as follows: Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities, and listed equities. Level 2 – Pricing inputs are other than quoted prices in active markets included in level 1, which are either directly or indirectly observable as of the reported date and includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors, and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options, and collars. Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value As of March 31, 2022, the Company believes the amounts reported for cash, payables, accrued liabilities and amounts due to related parties approximate their fair values due to the nature or duration of these instruments. The following table represents the change in the fair value of the derivative liabilities during the year ended March 31, 2022: Level 1 Level 2 Level 3 Fair value of derivative liability as of March 31, 2020 $ - $ - $ 603,836 Change in fair value at initial issuance 544,592 Change in fair value due to conversion of debt (199,567 ) Change in fair value of derivative (646,705 ) Fair value of derivative liability as of March 31, 2021 $ - $ - $ 302,156 Change in fair value at initial issuance - - 166,667 Change in fair value of the derivative - - (468,823 ) Balance at March 31, 2022 $ - $ - $ -

GOING CONCERN

GOING CONCERN	12 Months Ended
	Mar. 31, 2022
GOING CONCERN
NOTE 3 - GOING CONCERN	NOTE 3 – GOING CONCERN The Company’s consolidated financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company, as shown in the accompanying consolidated balance sheets, has working capital deficit of $671,477 and an accumulated deficit of $18,821,806 as of March 31, 2022. The Company does not have a source of revenue to cover its operating costs. These factors raise substantial doubt about the company’s ability to continue as a going concern. The Company will engage in research and development activities that must be satisfied in cash secured through outside funding. The Company will offer noncash consideration and seek equity lines as a means of financing its operations. If the Company is unable to obtain revenue producing contracts or financing or if the revenue or financing it does obtain is insufficient to cover any operating losses it may incur, it may substantially curtail or terminate its operations or seek other business opportunities through strategic alliances, acquisitions or other arrangements that may dilute the interests of existing stockholders.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Mar. 31, 2022
RELATED PARTY TRANSACTIONS
NOTE 4 - RELATED PARTY TRANSACTIONS	NOTE 4 – RELATED PARTY TRANSACTIONS On September 1, 2020, the Company entered five-year compensation agreements with two of its officers and an independent director. Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 18% of the outstanding shares of the Company as additional future shares are issued. The officers and directors are entitled to additional future shares so their aggregate ownership percentage remains at 18% of the future outstanding shares of the Company. In addition, the officers ae entitled to future bonuses including a signing bonus totaling $170,000 which was accrued during the period ending March 31, 2022 plus additional bonuses based on their performance. Officer and Director Fiscal Year Annualized Compensation Base Being Paid Non-dilutive shares percentage President and CEO (2) $ 252,000 12 % Chief Financial Officer (1) $ 180,000 6 % Director (3) $ 20,000 - Total $ 452,000 18 % For the year ended March 31, 2022: (1) The Chief Financial Officers was paid $144,000 in cash and accrued $36,000 in compensation. The $36,000 that was accrued, was paid in common stock of the Company. (2) The President and Chief Executive Officer was paid $221,500 and accrued $30,500 in compensation. The $30,500 that was accrued, was paid in common stock of the Company. (3) The director of the Company was paid $20,000 in director fees which was paid in stock. The following table sets forth the shares earned under these contracts from inception through year ended March 31, 2022: Officer and Director Initial Share Awards Under the Contracts Additional Shares Earned to Maintain Ownership Percentage Total Shares Earned President 1,028,910 7,607,269 8,636,179 Chief Financial Officer 617,346 4,036,223 4,653,569 Total 1,646,256 11,643,492 13,289,748 As of March 31, 2022, the Company had zero due to officers and directors. During the year ended March 31, 2021 four officers and directors were issued 9,372,909 shares of common stock with a value of $575,412 for service. During the year ended March 31, 2021 three officers of the Company converted $1,577,471 of accrued compensation into 16,931,101 shares of common stock of the Company. During the year ended March 31, 2021 the Company paid the related parties (three officers and directors) $216,500 in consulting fees in cash and accrued $308,833 of the consulting fees for a total of $525,333. During the year ended March 31, 2021 an officer of the Company advanced the Company $26,418, $14,000 in payment of accounts payable, 10,384 in cash. The Company repaid $30,910 during the year from a balance of the previous year of $21,876 and $7,000 from this year’s advances, leaving a balance due of $17,384. The balance was paid on April 19, 2021. During the year ended March 31, 2022 two officers and a director converted $128,333 of accrued payables into 2,407,010 shares of common stock. During the year ended March 31, 2022 the Company issued 540,000 shares of Common stock to an individual for account payable with a value of $27,000. During the year ended March 31, 2022 the Company issued 50,000 shares of common stock with a value of $5,250 for service During the year ended March 31, 2022 the Company issued 1,968,363 shares of common stock for the conversion of 54,130 shares of preferred stock. During the year ended March 31, 2022 the Company issued 1,513,719 shares of common stock with a value of $110,835 to three related parties for service. In December 2021, an officer of the Company advanced the Company $21,220, $14,220 for accounts payable and $7,000 in cash. The Company repaid the advance on February 9, 2022.

LICENSE SETTLEMENT

LICENSE SETTLEMENT	12 Months Ended
	Mar. 31, 2022
LICENSE SETTLEMENT
NOTE 5 - LICENSE SETTLEMENT	NOTE 5 – LICENSE SETTLEMENT On October 12, 2017, the Company signed a consulting agreement with a former license holder. Under the terms of the agreement the Company, commencing February 1, 2018 will pay the consultant $1,000 per month for 24 months. In addition, the Company will pay the consultant an additional $24,000 during the term of the agreement at the Company’s discretion. In return, the consultant forgave all royalty payments plus any past claims to the product per the previous agreement dated September 21, 2015, plus provide consulting services to the Company as directed by the Company. As of March 31, 2022, the consultant is owed $12,000 .

EQUITY

EQUITY	12 Months Ended
	Mar. 31, 2022
EQUITY
NOTE 6 - EQUITY	NOTE 6 – EQUITY On July 9, 2020, the Company increased its authorized shares to 550,000,000 consisting of 50,000,000 preferred shares and 500,000,000 common shares all at par value $0.001. Preferred Stock On July 10, 2019, the Company filed an amended articles of Incorporation designating 1,500,000 shares of preferred stock as Series A non-voting Convertible preferred shares convertible into common stock at four shares of common for each one share of preferred. On July 25, 2019, the Company issued 110,000 shares at $1.00 per share of series A convertible preferred to one entity with a value of $110,000 for cash. Each share of series A preferred is convertible after 180 days to four shares of common stock ($0.25 per share) or at the lowest of: (i) the fixed conversion price; (ii) the equitant of 70% of the lowest closing price for the 20 days prior to the conversion of the preferred shares and accrues 7% interest annually. During the year ended March 31, 2021 the Company issued 740,000 shares of Series A preferred stock and 3,700,000 warrants; 640,000 for $640,000 in cash and $100,000 for debt. The stock is convertible into common stock at 10 cents per share or 50% of the lowest trading price, whichever is lower 5 days prior to conversion. The Company has the right to convert the shares nine months after the issuance. The warrants are convertible at $0.15 per share within two years of issuance. In addition the Company agreed to filing an S-1 by September 21, 2020 for the common stock to be converted and the underlying common shares for the warrants. The S-1 was filed. During the year ended March 31, 2021 the Company issued 26,657,443 shares of common stock for the conversion of 745,870 shares of preferred stock and $14,013 in interest. During the year ended March 31, 2022 the Company issued 1,968,363 shares of common stock for the conversion of 54,130 shares of preferred stock. As of March 31, 2022 there we no preferred shares outstanding. Common Stock During the year ended March 31, 2021, four officers and directors were issued 9,372,909 shares of common stock with a value of $575,412 for service. During the year ended March 31, 2021, three officers of the Company converted $1,577,471 of accrued compensation into 16,931,101 shares of common stock of the Company. During the year ended March 31, 2021, the Company issued 26,657,443 shares of common stock for the conversion of 746,000 shares of preferred stock and $14,013 in interest. During the year ended March 31, 2021, the Company issued 577,287 shares of common stock with a value of $44,801 for accounts payable. During the year ended March 31, 2021, the Company issued 2,422,902 shares of common stock with a value of $210,440 for service. During the year ended March 31, 2021, the Company issued 3,982,179 shares of common stock with a value of $199,567 for the conversion of debt. During the year ended March 31, 2022 two officers and a director converted $128,333 of accrued payables into 2,407,010 shares of common stock. During the year ended March 31, 2022 the Company issued 540,000 shares of Common stock to an individual for account payable with a value of $27,000. During the year ended March 31, 2022 the Company issued 50,000 shares of common stock with a value of $5,250 for service During the year ended March 31, 2022 the Company issued 1,968,363 shares of common stock for the conversion of 54,130 shares of preferred stock. During the year ended March 31, 2022 the Company issued 1,513,719 shares of common stock with a value of $110,835 to three related parties for service.

OPTIONS

OPTIONS	12 Months Ended
	Mar. 31, 2022
OPTIONS
NOTE 7 - OPTIONS	NOTE 7 – OPTIONS The Company under its 2015 option plan issues options to various officers, directors, and consultants. The options vest in equal annual installments over a five year period with the first 20% vested when the options were granted. All of the options are exercisable at a purchase price based on the last trading price of the Company’s common stock on the date of grant and have a term of 10 years. On April 1, 2016, the Company issued 40,000 options to a consultant under the 2015 option program. The options are exercisable into the Company’s common stock at $0.30 per share, have term of 10 years and vest in 5 equal annual installments with the first installment vesting on the date of grant. This award to a nonemployee is revalued at each reporting period until completion of services. On April 1, 2016, the Company entered a consulting agreement under which the consultant was granted 30,000 options. In addition, the consultant received additional option grants of 30,000 options on April 1, 2017 and 40,000 options on April 1, 2018. The options are exercisable into the Company’s common stock at $0.30 per share, have term of 10 years and vest in 5 equal annual installments with the first installment vesting on the date of grant. On July 20, 2016, the Company granted from the 2015 Option Program 300,000 options each to three officers and directors for a total of 900,000 options being granted. The options are exercisable into the Company’s common stock at an exercise price of $0.301 per share and were vested and expensed at the date of issuance. The fair value at date of granted was determined to be $484,205. On April 1, 2018, the Company granted from the 2015 Option Program 40,000 options to one consultant. The options are exercisable into the Company’s common stock at an exercise price of $0.25 per share and were vested and expensed at the date of issuance. The fair value at date of granted was determined to be $9,991. During the years ended March 31, 2022 and 2021, the Company expensed zero, respectively related to its option awards. The unrecognized future balance to be expensed over the remaining vesting term of the options is zero as of March 31, 2022 and 2021. The following sets forth the options granted and outstanding during the years ended March 31, 2022 and 2021: Options Weighted Average Exercise Price Weighted Average Remaining Contract Life Number of Options Exercisable Intrinsic Value Outstanding at March 31, 2020 1,405,000 $ 0.34 6.80 1,397,000 $ - Granted -- -- --- -- -- Exercised -- -- -- -- -- Forfeited -- -- -- -- -- Outstanding at March 31, 2021 1,405,000 $ 0.34 5.80 1,405,000 $ - Granted -- -- -- -- -- Exercised -- -- -- -- -- Forfeited (475,000 ) ---- (475,000 ) -- Outstanding at March 31, 2022 930,000 $ 0.34 4.80 930,000 $ -

WARRANTS

WARRANTS	12 Months Ended
	Mar. 31, 2022
WARRANTS
NOTE 8 - WARRANTS	NOTE 8 – WARRANTS During the year ended March 31, 2021, the Company granted 3,700,000 warrants to four entities as part of the issuance of 740,000 Series A convertible preferred shares. The warrants expire in two years from grant date and are convertible into common stock at $0.15 per share. The warrants contain an anti-dilution clause which become effective if any instrument is issued after the warrant issuance is converted into common stock at a price lower than the warrant conversion price. The Company used the Black Scholes Pricing model to estimate the fair value of the warrants as of grant date, using the following key inputs: market prices of the Company’s common stock at dates of grant between $0.08-0.11 per share, conversion price of $0.15, volatility of 312.5%-314.49% and discount rate of 0.14-0.16%. Based on the fair value of the common stock of $437,000 and value of the warrants of $349,605 the fair value of the warrants was calculated to be 41% of the total value or $303,000. During the year ended March 31, 2021 the valuation resulted in a deemed dividend from the down round calculation of $555,000 with a recalculated conversion price change to $0.04 per share. The weighted average remaining life and intrinsic value of the warrants as of March 31, 2022 was. Warrants Weighted Average Exercise Price Weighted Average Remaining Contract Life Intrinsic Value Outstanding at March 31, 2020 -- $ 0.00 0.00 $ - Granted 3,700,000 0.15 2.00 Exercised -- - -- -- Expired -- - -- -- Outstanding at March 31, 2021 3,700,000 $ 0.04 1.35 $ - Granted -- Exercised -- Expired -- Outstanding at March 31, 2022 3,700,000 $ 0.04 0.35 $ - As of March 31, 2022 there were 3,700,000 warrants outstanding.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Mar. 31, 2022
INCOME TAXES
NOTE 9 - INCOME TAXES	NOTE 9 – INCOME TAXES At March 31, 2022 and 2021, the Company had federal net operating loss carry forwards of approximately $11,786,575 and $11,466,695, respectively. Components of net deferred tax assets, including a valuation allowance, are as follows at March 31, 2022 and 2021: March 31, 2022 March 31, 2021 Deferred tax assets: Net operating loss $ 319,880 $ 172,915 Less: Valuation allowance (319,880 ) (172,915 ) Net deferred tax assets $ - $ - In assessing the recovery of the deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in the periods in which those temporary differences become deductible. Management considers the scheduled reversals of future deferred tax assets, projected future taxable income, and tax planning strategies in making this assessment. As a result, management determined it was more likely than not the deferred tax assets would not be realized as of March 31, 2022. Based on the recent change in corporation tax rates the Company calculated the deferred tax asset for the years ended March 31, 2022 and 2021 at 21%. The Company due to its loses has not filed US Corporate tax returns and is subject to examination back to March 31, 2015.

CONVERTIBLE DEBT

CONVERTIBLE DEBT	12 Months Ended
	Mar. 31, 2022
CONVERTIBLE DEBT
NOTE 10 - CONVERTIBLE DEBT	NOTE 10 – CONVERTIBLE DEBT On December 31, 2019, the Company signed a guaranteed interest rate of 7% Convertible note for $161,250 with an OID of $11,250. The note was funded on January 3, 2020 . The note is convertible into common stock of the Company after 180 days at the rate of 60% of the lowest trading price for twenty days prior to conversion or $0.078 whichever is lower. The note may be repaid to the issuer within 180 days from issuance at variable premium rates of 115% to 135% above face value calculated on the outstanding face value of the note plus guaranteed interest . On May 7, 2020, The Company issued an 8% $50,000 one year convertible note. The note was convertible into common stock at the lesser of $0.20 per share or 80% of the lowest closing bid five days prior to conversion. On July 7, 2020, $50,000 of the one year convertible note payable was converted into 50,000 shares of series A preferred On October 28, 2020, the Company issued a $138,000 convertible note with an OID of $10,000. The note matures on October 28, 2021 and bears interest at 10% per annum. After 180 days the note may be converted into common stock of the Company at $0.04 per share or a 30% discount to the VWAP during the 20 days prior to conversion. The initial derivative was calculated using risk free interest of .18%, volatility of 212% and expected life of .50 years. On April 20, 2021, note was paid with the principal of $138,000, accrued interest of $6,805 and financing costs of $41,400. On November 11, 2020, the Company issued a $82,500 convertible note with an OID of $7,500. The note matures on October 28,2021 with a fixed interest of 10%. After 180 days the note may be converted into common stock of the Company at a 35% discount to the lowest trading price during the 20 days prior to conversion. On April 22, 2021, the note was paid consisting of principal of $82,500, accrued interest of $8,250 and finance costs of $24,750. On February 16, 2021, the Company issued a $100,000 convertible note with an OID of $5,000. The note matures on February 16, 2022, and bears fixed interest of 10%. After 180 days the note may be converted into common stock of the Company at a 30% discount to the lowest trading price during the 15 days prior to conversion. The initial derivative was calculated using risk free interest of .18%, volatility of 213% and expected life of 1.00 years. On August 16, 2021, the note was paid consisting of principal of $100,000, accrued interest of $5,000 and financing costs off $35,000. On August 10, 2021, the Company issued a $200,000 convertible note. The note matures on February 10, 2022, and bears fixed interest of 10%. Within 180 days of issuance the note may be repaid at an escalating premium up to 125% of the face value of the note. After 180 days the note may be converted into common stock of the Company at $0.06 per share or a 25% discount to the lowest trading price during the 10 days prior to conversion. The initial derivative was calculated using risk free interest of .05%, volatility of 132% and expected life of 0.50 years. On March 28, 2022, the Note was paid consisting of $200,000 in principal, accrued interest of $9,972.60 and financing costs of $50,000.

LICENSE AGREEMENT

LICENSE AGREEMENT	12 Months Ended
	Mar. 31, 2022
LICENSE AGREEMENT
NOTE 11 - LICENSE AGREEMENT	NOTE 11 - LICENSE AGREEMENT On March 31, 2021, the Company issued a license agreement for US $5,000,000 to BioRay Pharmaceutical Co, LTD, (Licensee) licensing Pritumumab internationally with the exclusion of North and Central America and the Caribbean Islands. Under the terms of the agreement the Company receives $250,000 upon signing of the agreement plus $750,000 with the start of the phase 1 clinical trials , which started in March 2021. In addition, the Company received $750,000 upon the initial patient enrolled at the dosage level of 8.0 mg/kg. Further payment of $2,500,000 will be received when the FDA approves the phase 2 clinical trials and $750,000 when the phase 2 clinical trials begin. Upon commercialization by the Licensee, the Company will receive a 9% royalty on net sales for 20 years.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Mar. 31, 2022
COMMITMENTS AND CONTINGENCIES
NOTE 12 - COMMITMENTS AND CONTINGENCIES	NOTE 12 – COMMITMENTS AND CONTINGENCIES On June 30, 2016, the Company entered into a cell line sales agreement with the product manufacture. Under the terms of the agreement the company is obligated to make future payments based on the milestones of its achievements. These future payments may be as followed; 1. $100,000 upon the initiation (first dose/first patient) of the first Phase I clinical trial (or equivalent) of a product. 2. $225,000 upon the initiation (first dose/first patient) of the first Phase III clinical trial (or equivalent) of a product 3. $225,000 payable upon the first BLA approval (or equivalent) of a product. 4. Annual maintenance fee upon completion of phase I manufacturing or the transfer of the cell line from Catalent’s control of $50,000. 5. A contingent sales fee upon product sales of 1% of sales or $150,000 whichever is greater. As of March 31, 2022 the Company accrued $270,000 of maintenance fees plus interest of $28,000 for a total of $298,000. On March 9, 2020, the Board of Directors of the Company adapted an expense bonus program. Under the program, if an acquisition, merger or change in control is affected, 10% of the value of the transaction will be allocated to pay the expenses of the transaction including but not limited to legal, accounting, transfer fees and other miscellaneous expense. The balance of the fund after expenses will be allocation 20% to directors and 80% to officers and employees of the Company as allocated by the Chief Executive Officer and approved by the Board of Directors. On September 1, 2020, the Company entered five-year compensation agreements with two of its officers and directors. Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 18% of the outstanding shares of the Company as additional future shares are issued. The officers and directors are entitled to additional future shares so their aggregate ownership percentage remains at 18% of the future outstanding shares of the Company On October 30, 2020, the Company signed a term sheet with Alpha Holdings, Inc (Alpha) whereby Alpha, subject to a definitive agreement agreeable to both parties will invest US $ 5,000,000 in the Company. The term sheet outlines the terms of the agreement with a projected closure by December 31, 2020 for an initial investment of $2,500,000 and an additional investment of $2,500,000 on about April 30, 2021. The investment will be in the Company’s common stock to be priced at a low of nine cents per share and a high of 10 cents per share subject to a 90 day weighted average pricing before closing. Upon completion of the $5,000,000 investment Alpha may elect a majority of the board of directors of the Company. The Company determined that Alpha was treating this as an acquisition and not investment requiring control of the board of directors in the best interest of all shareholders the Company terminated it discussions with Alpha Holdings, Inc as of December 30, 2020.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Mar. 31, 2022
SUBSEQUENT EVENTS
NOTE 13 - SUBSEQUENT EVENTS	NOTE 13 - SUBSEQUENT EVENTS On April 4, 2022, the Company issued 1,000,000 shares of common stock for clinical consulting with a value of $60,000. On April 4, 2022, the Company issued a $275,000 one year convertible note with an OID of $25,000 and bearing interest at 8% per annum. In addition, the Company issued 500,000 18 months warrants with a conversion price of $0.12 per share. The Company may at its option issue an additional convertible note with the same terms and value as the note issued. On May 4, 2022, the Company issued 750,000 shares of common stock for the conversion of 750,000 warrants with a value of $30,000 received in cash. On June 14, 2022, the Company 1,950,000 shares of common stock for the conversion of 1,950,000 warrants with a value of $78,000 received in cash. The Company has evaluated subsequent events to determine events occurring after March 31, 2022 through June 15, 2022 that would have a material impact on the Company’s financial results or require disclosure and have determined none exist other than those noted above in this footnote.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Mar. 31, 2022
SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation	The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles. The Company has elected a fiscal year ending on March 31.
Principle of consolidation	The accompanying consolidated financial statements include the accounts of Nascent Biotech, Inc. and its wholly-owned subsidiary Nascent Biologics, Inc, which has been inactive since March 2015. All intercompany accounts and transactions have been eliminated.
Cash and Cash Equivalents	The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The Company as of March 31, 2022 did not have any cash equivalents.
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the periods. The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition, and results of operations is highly uncertain and subject to change. We considered the potential impact of the COVID-19 pandemic on our estimates and assumptions and there was not a material impact to our consolidated financial statements as of and for the year ended March 31, 2022. Actual results could differ from estimates making it reasonably possible that a change in the estimates could occur in the near term.
Revenue recognition	In April 2016, the FASB issued ASU 2016–10 Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. The amendments in this Update do not change the core principle of the guidance in Topic 606. Rather, the amendments in this Update clarify the following two aspects of Topic 606: identifying performance obligations and the licensing implementation guidance, while retaining the related principles for those areas. Topic 606 includes implementation guidance on (a) contracts with customers to transfer goods and services in exchange for consideration and (b) determining whether an entity’s promise to grant a license provides a customer with either a right to use the entity’s intellectual property (which is satisfied at a point in time) or a right to access the entity’s intellectual property (which is satisfied over time). The amendments are intended to render more detailed implementation guidance with the expectation to reduce the degree of judgement necessary to comply with Topic 606. ASC Topic 606 prescribes a new five-step model entities should follow in order to recognize revenue in accordance with the core principle. These five steps are: 1. Identify the contract(s) with a customer. 2. Identify the performance obligations in the contract. 3. Determine the transaction price. 4. Allocate the transaction price to the performance obligations in the contract. 5. Recognize revenue when (or as) the entity satisfied the performance obligations. The Company implemented the transition using the modified retrospective method of transition. The funds are not earned on milestones that have not been reached per the contract. Based on the cut off treatment of the recognition of revenue per the milestones specific to the license agreements, the Company has determined that there are no adjustments in the value of the revenue recognized from these contracts. The Company has one revenue stream, which is the milestone payments of the license agreement with BioRay Pharmaceutical which is not earned or billed until the milestone per the agreement is met.
Accounts receivable	Accounts receivable are carried at face value less any provisions for uncollectible amounts. Accounts receivable are receivables from a license agreement. No allowance for bad debt was considered necessary for the years ended March 31, 2022 and 2021, respectively.
Stock-Based Compensation	The Company accounts for stock-based compensation in accordance with the fair value recognition provision of the Financial Accounting Standards Board(“FASB”) Accounting Standards Codification (“ASC”) No 718. The Company issues restricted stock to employees and consultants for their services. Cost of these transactions are measured at fair value of the equity instrument issued at the date of grant. These shares are considered fully vested and the fair market value is recognized as the expense in the period granted. The Company recognized consulting expense and a corresponding increase to the additional paid in capital related to the stock issued for services. For agreements requiring future services the consulting expense is to be recognized ratably over the requisite service period.
Research and Development Expense	Research and development costs are expensed in the period they are incurred in accordance with ASC 730, Research and Development unless they meet specific criteria related to technical, market and financial feasibility, as determined by management, including but not limited to the establishment of a clearly defined future alternative use for the product, and the availability of adequate resources to complete the project. If all criteria are met, the costs are deferred and amortized over the expected useful life of the project or expensed as research and development as the material are consumed or written off if a product is abandoned. At March 31, 2022 and 2021, the Company had zero capitalized associated with materials held with a future alternative use. The cost of these materials was expensed as research and development as the materials are consumed or designated for usage. As the Company is preparing to begin clinical studies using a dose escalation method, it is not feasible to determine if the additional product will be needed for the brain cancer studies.
Property and Equipment	Property and equipment is recorded at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the expected useful life of the asset (3 to 5 years), beginning when the asset is available and ready for use. Expenditures associated with upgrades and enhancements that improve, add functionality, or otherwise extend the life of property and equipment are capitalized, while expenditures that do not, such as repairs and maintenance, are expensed as incurred. For the years ended March 31, 2022 and 2021, depreciation expense totaled zero, respectively.
Impairment of Long-Lived Assets	The Company reviews the carrying value of its long-lived assets annually or whenever events or changes in circumstances indicate that the historical-cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the asset by comparing the undiscounted future net cash flows expected to result from the asset to its carrying value. If the carrying value exceeds the undiscounted future net cash flows of the asset, an impairment loss is measured and recognized. An impairment loss is measured as the difference between the net book value and the fair value of the long-lived asset. Fair value is estimated based upon either discounted cash flow analysis or estimated salvage value. There was no impairment recognized during the years ended March 31, 2022 and 2021.
Income Taxes	Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company accounts for income taxes under the provisions of FASB ASC 740, Accounting for Income Taxes
Basic and Diluted Net Income (Loss) per Share	Basic net income (loss) per share calculations are calculated on the basis of the weighted average number of common shares outstanding during the year. During the year ended March 31, 2022 the Company had a net loss so the options and warrants outstanding were not part the loss per share calculation as they would be antidilutive. Diluted income (loss) per share calculations includes the dilutive effect of warrants and options on the weighted average of the per share calculation.
Fair Value of Financial Instruments	The Company’s financial instruments consist of cash and cash equivalents, accounts payable and accrued expenses and shareholder loans. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. As defined in (Financial Accounting Standards Board ASC 820), fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilized the market data of similar entities in its industry or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. FASB ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). The three levels of the fair value hierarchy are as follows: Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities, and listed equities. Level 2 – Pricing inputs are other than quoted prices in active markets included in level 1, which are either directly or indirectly observable as of the reported date and includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors, and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options, and collars. Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value As of March 31, 2022, the Company believes the amounts reported for cash, payables, accrued liabilities and amounts due to related parties approximate their fair values due to the nature or duration of these instruments. The following table represents the change in the fair value of the derivative liabilities during the year ended March 31, 2022: Level 1 Level 2 Level 3 Fair value of derivative liability as of March 31, 2020 $ - $ - $ 603,836 Change in fair value at initial issuance 544,592 Change in fair value due to conversion of debt (199,567 ) Change in fair value of derivative (646,705 ) Fair value of derivative liability as of March 31, 2021 $ - $ - $ 302,156 Change in fair value at initial issuance - - 166,667 Change in fair value of the derivative - - (468,823 ) Balance at March 31, 2022 $ - $ - $ -

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Mar. 31, 2022
SIGNIFICANT ACCOUNTING POLICIES (Tables)
Schedule of Summarizes of change in the fair value of the derivative liabilities	Level 1 Level 2 Level 3 Fair value of derivative liability as of March 31, 2020 $ - $ - $ 603,836 Change in fair value at initial issuance 544,592 Change in fair value due to conversion of debt (199,567 ) Change in fair value of derivative (646,705 ) Fair value of derivative liability as of March 31, 2021 $ - $ - $ 302,156 Change in fair value at initial issuance - - 166,667 Change in fair value of the derivative - - (468,823 ) Balance at March 31, 2022 $ - $ - $ -

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	12 Months Ended
	Mar. 31, 2022
RELATED PARTY TRANSACTIONS (Tables)
Schedule of shares earned by related party	Officer and Director Initial Share Awards Under the Contracts Additional Shares Earned to Maintain Ownership Percentage Total Shares Earned President 1,028,910 7,607,269 8,636,179 Chief Financial Officer 617,346 4,036,223 4,653,569 Total 1,646,256 11,643,492 13,289,748
Schedule of annual salary and annual severance amounts	Officer and Director Fiscal Year Annualized Compensation Base Being Paid Non-dilutive shares percentage President and CEO (2) $ 252,000 12 % Chief Financial Officer (1) $ 180,000 6 % Director (3) $ 20,000 - Total $ 452,000 18 %

OPTIONS (Tables)

OPTIONS (Tables)	12 Months Ended
	Mar. 31, 2022
OPTIONS
Schedule of Summary of stock options aoutstanding	Options Weighted Average Exercise Price Weighted Average Remaining Contract Life Number of Options Exercisable Intrinsic Value Outstanding at March 31, 2020 1,405,000 $ 0.34 6.80 1,397,000 $ - Granted -- -- --- -- -- Exercised -- -- -- -- -- Forfeited -- -- -- -- -- Outstanding at March 31, 2021 1,405,000 $ 0.34 5.80 1,405,000 $ - Granted -- -- -- -- -- Exercised -- -- -- -- -- Forfeited (475,000 ) ---- (475,000 ) -- Outstanding at March 31, 2022 930,000 $ 0.34 4.80 930,000 $ -

WARRANTS (Tables)

WARRANTS (Tables)	12 Months Ended
	Mar. 31, 2022
WARRANTS
Schedule of Summary of warrants outstanding	Warrants Weighted Average Exercise Price Weighted Average Remaining Contract Life Intrinsic Value Outstanding at March 31, 2020 -- $ 0.00 0.00 $ - Granted 3,700,000 0.15 2.00 Exercised -- - -- -- Expired -- - -- -- Outstanding at March 31, 2021 3,700,000 $ 0.04 1.35 $ - Granted -- Exercised -- Expired -- Outstanding at March 31, 2022 3,700,000 $ 0.04 0.35 $ -

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Mar. 31, 2022
INCOME TAXES
Schedule of Components of net deferred tax assets	March 31, 2022 March 31, 2021 Deferred tax assets: Net operating loss $ 319,880 $ 172,915 Less: Valuation allowance (319,880 ) (172,915 ) Net deferred tax assets $ - $ -

ORGANIZATION AND NATURE OF OP_2

ORGANIZATION AND NATURE OF OPERATIONS (Details Narrative) - USD ($)	Mar. 31, 2022	Mar. 31, 2021	Jul. 15, 2014
Common stock, outstanding shares	111,313,175	104,834,083
Jin-En [Member]
Common stock, issued shares			7,500,200
Common stock, shares cancelled			15,000,000
Common stock, outstanding shares			22,829,400
Net liablilities			$ 19,000

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Level 1 [Member]
Begnning Balance	$ 0	$ 0
Change in fair value at initial issuance	0
Change in fair value of the derivative	0
Ending Balance	0	0
Level 3 [Member]
Begnning Balance	302,156	603,836
Change in fair value at initial issuance	166,667	544,592
Change in fair value of the derivative	(468,823)	(646,705)
Ending Balance	0	302,156
Change in fair value due to conversion of debt		(199,567)
Level 2 [Member]
Begnning Balance	0	0
Change in fair value at initial issuance	0
Change in fair value of the derivative	0
Ending Balance	$ 0	$ 0

SIGNIFICANT ACCOUNTING POLICI_5

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Depreciation expense	$ 0	$ 0
Maximum [Member]
Expected life in years	5 years
Minimum [Member]
Expected life in years	3 years

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	Mar. 31, 2022	Mar. 31, 2021
GOING CONCERN
Working capital deficit	$ (671,477)
Accumulated Deficit	$ (18,821,806)	$ (18,351,416)

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details)	12 Months Ended
	Mar. 31, 2022USD ($)
Fiscal Year Annualized Compensation Being Paid	$ 452,000
Non-dilutive shares, percentage	18.00%
Director [Member]
Fiscal Year Annualized Compensation Being Paid	$ 20,000
Non-dilutive shares, percentage	0.00%
President [Member]
Fiscal Year Annualized Compensation Being Paid	$ 252,000
Non-dilutive shares, percentage	12.00%
Chief Financial Officer [Member]
Fiscal Year Annualized Compensation Being Paid	$ 180,000
Non-dilutive shares, percentage	6.00%

RELATED PARTY TRANSACTIONS (D_2

RELATED PARTY TRANSACTIONS (Details 1)	12 Months Ended
	Mar. 31, 2022shares
Initial Share Awards Under the Contracts	1,646,256
Additional Shares Earned to Maintain Ownership Percentage	11,643,492
Total Shares Earned	13,289,748
President [Member]
Initial Share Awards Under the Contracts	1,028,910
Additional Shares Earned to Maintain Ownership Percentage	7,607,269
Total Shares Earned	8,636,179
Chief Financial Officer [Member]
Initial Share Awards Under the Contracts	617,346
Additional Shares Earned to Maintain Ownership Percentage	4,036,223
Total Shares Earned	4,653,569

RELATED PARTY TRANSACTIONS (D_3

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	Apr. 04, 2022	Mar. 31, 2022	Mar. 31, 2021	Mar. 28, 2022	Dec. 31, 2021	Apr. 22, 2021	Apr. 20, 2021	Apr. 16, 2021
Due to related party		$ 0	$ 123,217
Cash					$ 7,000
Advanced payment					21,220
Common stock shares issued for services, amount	$ 60,000	$ 110,835	210,440
Common stock shares issued for services, shares	1,000,000	1,513,719
Accounts payable		$ 27,000	14,000		$ 14,220
Account payable, shares		540,000
Accrued bonus				$ 9,972		$ 8,250	$ 6,805	$ 5,000
Conversion of preferred stock shares issued		54,130
Consulting fees		$ 547,933	1,469,171
September 1, 2020 [Member]
Officers and directors employment agreement terms, description		Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 18% of the outstanding shares of the Company as additional future shares are issued. The officers and directors are entitled to additional future shares so their aggregate ownership percentage remains at 18% of the future outstanding shares of the Company.
Bonus amount		$ 170,000
President And Chief Executive Officer [Member]
Cash		221,500
Accrued consulting fees		30,500
Accrued bonus		30,500
Chief Financial Officers [Member]
Cash		144,000
Accrued consulting fees		36,000
Accrued bonus		$ 36,000
Conversion of preferred stock shares issued		54,130
Accrued fees converted amount, shares		1,968,363
Three Officers and Director [Member] | September 1, 2015 [Member]
Cash			308,833
Accrued consulting fees		$ 20,000	216,500
Consulting fees			525,333
Officer And Director [Member]
Cash		126,500	10,384
Accounts payable		27,000	14,000
Repaid amount			30,910
Advance from related party			26,418
Balance due			17,384
Advances			7,000
Proceeds from related party			21,876
Four Officers And Directors [Member]
Common stock shares issued for services, amount			$ 575,412
Common stock shares issued for services, shares			9,372,909
Three Officers [Member]
Debt conversion, converted instrument, shares			16,931,101
Debt conversion, converted instrument, amount			$ 1,577,471
Two Officers and Director [Member]
Common stock shares issued for services, amount		$ 128,333
Common stock shares issued for services, shares		2,407,010
Accrued fees converted amount, shares		1,968,363
Two Officers and Director One [Member]
Common stock shares issued for services, amount		$ 5,250
Common stock shares issued for services, shares		50,000

LICENSE SETTLEMENT (Details Nar

LICENSE SETTLEMENT (Details Narrative)	Oct. 12, 2017USD ($)integer	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)
Consulting fees		$ 547,933	$ 1,469,171
Consulting agreement [Member]
Number of installments, consideration for license | integer	24
Monthly installment payment	$ 1,000
Consulting fees payable	$ 24,000
Consulting fees		$ 12,000

EQUITY (Details Narrative)

EQUITY (Details Narrative) - USD ($)	Apr. 04, 2022	Aug. 10, 2021	Nov. 11, 2020	Jul. 07, 2020	Feb. 16, 2021	Oct. 28, 2020	Jul. 25, 2019	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020	Jul. 09, 2020	Jul. 10, 2019
Settlemet of accounts payable									$ 44,801
Common stock shares issued upon conversion of debt, amount									199,567
Common stock shares value for services, amount	$ 60,000							$ 110,835	$ 210,440
Total no of authorized shares											550,000,000
Preferred stock shares authorized								50,000,000	50,000,000		50,000,000
Common stock shares authorized								500,000,000	500,000,000		500,000,000
Preferred stock shares designated												1,500,000
Conversion of preferred stock shares issued								54,130
Common shares issued, for settlement of accounts payable									577,287
Common stock, price per share								$ 1	$ 1
Preferred stock shares									$ 740,000
Preferred stock shares, value								$ 0
Common stock share issued for cash, amount								$ 27,000	$ 44,081
Common stock shares issued for services	1,000,000							1,513,719
Common stock shares issued upon conversion of debt, shares										757,142
Common stock shares, issued								111,313,175	104,834,083
Common Stock One [Member]
Common stock share issued for cash, amount								$ 5,250
Common stock share issued for cash, shares								50,000	26,657,443
Common Stock Two [Member]
Common stock shares value for services, amount								$ 110,835	$ 210,440
Common stock shares issued for services								1,513,719	2,422,902
Common Stock Three [Member]
Conversion of preferred stock shares issued								54,130
Common stock shares issued upon conversion of debt, shares								1,968,363	3,982,179
Series A Convertible Preferred Stock [Member]
Conversion of preferred stock shares issued									745,870
Preferred stock shares, value							$ 110,000
Common stock shares issued upon conversion of debt, shares				50,000
Interest									$ 14,013
Common stock shares, issued									26,657,443
Preferred stock, shares issued							110,000		746,000
Conversion description		Within 180 days of issuance the note may be repaid at an escalating premium up to 125% of the face value of the note. After 180 days the note may be converted into common stock of the Company at $0.06 per share or a 25% discount to the lowest trading price during the 10 days prior to conversion. The initial derivative was calculated using risk free interest of .05%, volatility of 132% and expected life of 0.50 years.	After 180 days the note may be converted into common stock of the Company at a 35% discount to the lowest trading price during the 20 days prior to conversion.		After 180 days the note may be converted into common stock of the Company at a 30% discount to the lowest trading price during the 15 days prior to conversion. The initial derivative was calculated using risk free interest of .18%, volatility of 213% and expected life of 1.00 years.	After 180 days the note may be converted into common stock of the Company at $0.04 per share or a 30% discount to the VWAP during the 20 days prior to conversion. The initial derivative was calculated using risk free interest of .18%, volatility of 212% and expected life of .50 years.	Each share of series A preferred is convertible after 180 days to four shares of common stock ($0.25 per share) or at the lowest of: (i) the fixed conversion price; (ii) the equitant of 70% of the lowest closing price for the 20 days prior to the conversion of the preferred shares and accrues 7% interest annually.
Outstanding warrants, granted									3,700,000
Preferred stock issued for cash, shares									640,000
Debt									$ 100,000
Convertible, description									The stock is convertible into common stock at 10 cents per share or 50% of the lowest trading price, whichever is lower 5 days prior to conversion. The Company has the right to convert the shares nine months after the issuance. The warrants are convertible at $0.15 per share within two years of issuance.
Two Officers and Director [Member]
Common stock shares value for services, amount								$ 128,333
Common stock shares issued for services								2,407,010
Accrued fees converted amount, shares								1,968,363
Common stock shares issued for compensation, value									$ 1,577,471
Common stock shares issued for compensation, shares									16,931,101
Two Officers and Director One [Member]
Common stock shares value for services, amount								$ 5,250
Common stock shares issued for services								50,000
Common stock shares value for account payable, amount								$ 27,000
Common stock shares value for account payable								540,000
Four Officers and Director [Member]
Common stock shares value for services, amount									$ 575,412
Common stock shares issued for services									9,372,909

OPTIONS (Details)

OPTIONS (Details) - USD ($)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Options
Number of option exercisable, Beginning	1,405,000	1,405,000
Outstanding option, Forfeited	$ (475,000)
Number of option exercisable, Ending	930,000	1,405,000
Weighted average exercise price
Weighted average exercise price, Beginning	$ 0.34	$ 0.34
Weighted average exercise price, Ending	$ 0.34	$ 0.34
Weighted Average Remaining Contract Life
Weighted Average Remaining Contract life, Beginning	5 years 9 months 18 days	6 years 9 months 18 days
Weighted Average Remaining Contract life, Ending	4 years 9 months 18 days	5 years 9 months 18 days
Number of option exercisable
Outstanding option, Forfeited	(475,000)
Outstanding option, Beginning	1,405,000	1,397,000
Outstanding option, Ending	930,000	1,405,000
Intrinsic value
Intrinsic value, Beginning		$ 0
Intrinsic value, Ending	$ 0	$ 0

OPTIONS (Details Narrative)

OPTIONS (Details Narrative)	1 Months Ended	12 Months Ended
	Jul. 20, 2016USD ($)$ / sharesshares	Mar. 31, 2022USD ($)integer$ / sharesshares
Vest percentage at grant		20.00%
Common stock exercisable term		10 years
Options vested description		The options vest in equal annual installments over a five year period with the first 20% vested when the options were granted.
Option 1 [Member] | April 1, 2018 [Member]
Common stock exercisable term		10 years
Exercise price of options | $ / shares		$ 0.30
Number of installments vest | integer		5
Options granted		40,000
Option 1 [Member] | April 1, 2016 [Member]
Common stock exercisable term		10 years
Exercise price of options | $ / shares		$ 0.30
Number of installments vest | integer		5
Options granted		30,000
Issued options		40,000
Option 1 [Member] | April 1, 2017 [Member]
Options granted		30,000
Option 2 [Member] | April 1, 2018 [Member]
Exercise price of options | $ / shares	$ 0.301	$ 0.25
Options granted	900,000
Issued options	300,000	40,000
Fair value of option granted | $	$ 484,205	$ 9,991

WARRANTS (Details)

WARRANTS (Details) - USD ($)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Number of warrants
Outstanding warrants, Beginning	3,700,000	0
Outstanding warrants, granted		3,700,000
Outstanding warrants, Exercised		0
Outstanding warrants, Ending	3,700,000	3,700,000
Weighted average exercise price
Weighted average exercise price, Beginning	$ 0.04	$ 0
Weighted average exercise price, Granted		0.15
Weighted average exercise price, Expired		0
Weighted average exercise price, Exercised		0
Weighted average exercise price, Ending	$ 0.04	$ 0.04
Weighted Average Remaining Contract Life
Weighted Average Remaining Contract life, Beginning	1 year 4 months 6 days	0 years
Weighted Average Remaining Contract life, Granted		2 years
Weighted Average Remaining Contract life, Ending	4 months 6 days	1 year 4 months 6 days
Intrinsic value
Intrinsic value, Beginning	$ 0	$ 0
Intrinsic value, Ending	$ 0	$ 0

WARRANTS (Details Narrative)

WARRANTS (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2022
Deemed dividend from down round	$ 555,000
Warrants outstanding		3,700,000
Warrant [Member]
Exercise price of warrants	$ 0.15
Fair value of warrants	$ 303,000
Warrants granted	3,700,000
Fair value of common stock	$ 437,000
Warrants conversion price	$ 0.15
Warrants descriptions	the Company granted 3,700,000 warrants to four entities as part of the issuance of 740,000 Series A convertible preferred shares.
Proceeds from exercise of warrants	$ 349,605
Maximum [Member] | Warrant [Member]
Exercise price of warrants	$ 0.11
Volatility rate	314.49%
Discount rate	0.16%
Minimum [Member] | Warrant [Member]
Exercise price of warrants	$ 0.08
Volatility rate	312.50%
Discount rate	0.14%

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	Mar. 31, 2022	Mar. 31, 2021
Deferred tax assets:
Net operating loss	$ 319,880	$ 172,915
Less: Valuation allowance	(319,880)	(172,915)
Net deferred tax assets	$ 0	$ 0

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
INCOME TAXES
Federal net operating loss carry forwards	$ (11,786,575)	$ (11,466,695)
Federal tax rate	21.00%	21.00%

CONVERTIBLE DEBT (Details Narra

CONVERTIBLE DEBT (Details Narrative) - USD ($)

Aug. 10, 2021

Nov. 11, 2020

Jul. 07, 2020

May 07, 2020

Mar. 28, 2022

Apr. 22, 2021

Apr. 20, 2021

Apr. 16, 2021

Feb. 16, 2021

Oct. 28, 2020

Dec. 31, 2019

Jul. 25, 2019

Mar. 31, 2020

Debt conversion, principle balance

$ 200,000

$ 82,500

$ 138,000

$ 100,000

Accrued interest

9,972

8,250

6,805

5,000

Financing costs

$ 50,000

$ 24,750

$ 41,400

$ 35,000

Common stock shares issued upon conversion of debt

757,142

7% Convertible Note [Member]

Convertible debt

$ 161,250

Conversion price, Description

The note is convertible into common stock of the Company after 180 days at the rate of 60% of the lowest trading price for twenty days prior to conversion or $0.078 whichever is lower. The note may be repaid to the issuer within 180 days from issuance at variable premium rates of 115% to 135% above face value calculated on the outstanding face value of the note plus guaranteed interest .

Original issue discount

$ 11,250

8% Convertible Note [Member]

Convertible debt

$ 50,000

$ 50,000

Conversion price, Description

The note was convertible into common stock at the lesser of $0.20 per share or 80% of the lowest closing bid five days prior to conversion.

Series A Convertible Preferred Stock [Member]

Debt conversion, principle balance

$ 200,000

$ 7,500

$ 5,000

$ 10,000

Common stock shares issued upon conversion of debt

50,000

Convertible debt

$ 82,500

$ 100,000

$ 138,000

Conversion price, Description

Within 180 days of issuance the note may be repaid at an escalating premium up to 125% of the face value of the note. After 180 days the note may be converted into common stock of the Company at $0.06 per share or a 25% discount to the lowest trading price during the 10 days prior to conversion. The initial derivative was calculated using risk free interest of .05%, volatility of 132% and expected life of 0.50 years.

After 180 days the note may be converted into common stock of the Company at a 35% discount to the lowest trading price during the 20 days prior to conversion.

After 180 days the note may be converted into common stock of the Company at a 30% discount to the lowest trading price during the 15 days prior to conversion. The initial derivative was calculated using risk free interest of .18%, volatility of 213% and expected life of 1.00 years.

After 180 days the note may be converted into common stock of the Company at $0.04 per share or a 30% discount to the VWAP during the 20 days prior to conversion. The initial derivative was calculated using risk free interest of .18%, volatility of 212% and expected life of .50 years.

Each share of series A preferred is convertible after 180 days to four shares of common stock ($0.25 per share) or at the lowest of: (i) the fixed conversion price; (ii) the equitant of 70% of the lowest closing price for the 20 days prior to the conversion of the preferred shares and accrues 7% interest annually.

Risk free interest rate

10.00%

10.00%

10.00%

Debt maturity date

Feb. 10, 2022

Oct. 28, 2021

Feb. 16, 2022

Oct. 28, 2021

Interest rate

10.00%

LICENSE AGREEMENT (Details Narr

LICENSE AGREEMENT (Details Narrative) - BioRay Pharmaceutical Co LTD [Member]	12 Months Ended
	Mar. 31, 2022USD ($)
Agreement description	Under the terms of the agreement the Company receives $250,000 upon signing of the agreement plus $750,000 with the start of the phase 1 clinical trials , which started in March 2021. In addition, the Company received $750,000 upon the initial patient enrolled at the dosage level of 8.0 mg/kg. Further payment of $2,500,000 will be received when the FDA approves the phase 2 clinical trials and $750,000 when the phase 2 clinical trials begin.
Issuance of license agreement	$ 5,000,000
Royalty rate	9.00%
Net sales	20 years

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	Mar. 09, 2020	Oct. 30, 2020	Sep. 30, 2020	Jun. 30, 2016	Mar. 31, 2020	Mar. 31, 2022
Contingent sales fee description				A contingent sales fee upon product sales of 1% of sales or $150,000 whichever is greater.
Accrued fees						$ 270,000
Accrued interest						$ 28,000
Merger, description	Under the program, if an acquisition, merger or change in control is affected, 10% of the value of the transaction will be allocated to pay the expenses of the transaction including but not limited to legal, accounting, transfer fees and other miscellaneous expense. The balance of the fund after expenses will be allocation 20% to directors and 80% to officers and employees of the Company as allocated by the Chief Executive Officer and approved by the Board of Directors.		Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 18% of the outstanding shares of the Company as additional future shares are issued. The officers and directors are entitled to additional future shares so their aggregate ownership percentage remains at 18% of the future outstanding shares of the Company
Annual Maintenance					$ 298,000
First BLA [Member]
Future payments				$ 225,000
First Phase III clinical trial [Member]
Future payments				225,000
First Phase I clinical trial [Member]
Future payments				100,000
Annual maintenance fee				$ 50,000
Alpha Holding Inc [Member]
Initial investment		$ 2,500,000
Additional investment		2,500,000
Agreement from related party		$ 5,000,000
Investment description		The investment will be in the Company’s common stock to be priced at a low of nine cents per share and a high of 10 cents per share subject to a 90 day weighted average pricing before closing. Upon completion of the $5,000,000 investment

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Jun. 14, 2022	May 04, 2022	Apr. 04, 2022	Mar. 31, 2022	Mar. 31, 2021
Common stock shares value for services, amount			$ 60,000	$ 110,835	$ 210,440
Warrants exercised	1,950,000	750,000
Common stock value issued for services			1,000,000	1,513,719
Subsequent Event [Member]
Warrants exercised	1,950,000	750,000	500,000
Warrants exercised value	$ 78,000	$ 30,000
Warrant term			18 years
Exercise price			$ 0.12
Subsequent Event [Member] | Convertible Debt [Member]
Convertible note issued			$ 275,000
Interest rate			8.00%
Convertible notes payable			$ 25,000